Roxadustat + Epoetin alfa + Darbepoetin alfa + Iron

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anemia

Conditions

Anemia, End Stage Renal Disease (ESRD)

Trial Timeline

Nov 21, 2014 → Jul 6, 2018

About Roxadustat + Epoetin alfa + Darbepoetin alfa + Iron

Roxadustat + Epoetin alfa + Darbepoetin alfa + Iron is a phase 3 stage product being developed by Astellas Pharma for Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02278341. Target conditions include Anemia, End Stage Renal Disease (ESRD).

What happened to similar drugs?

20 of 20 similar drugs in Anemia were approved

Approved (20) Terminated (5) Active (0)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02278341Phase 3Completed

Competing Products

20 competing products in Anemia

See all competitors
ProductCompanyStageHype Score
Aranesp®AmgenApproved
43
KER-047Keros TherapeuticsPhase 2
17
LY2787106Eli LillyPhase 1
29
R744 + R744Chugai PharmaceuticalPhase 3
40
epoetin beta + placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
40
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
40
darbepoetin alfaAmgenPhase 3
40
PrasugrelDaiichi SankyoPhase 1
29
Prasugrel + PlaceboDaiichi SankyoPhase 2
35
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
AlefaceptAstellas PharmaPhase 1
21
RoxadustatAstellas PharmaPhase 2
35
roxadustatAstellas PharmaPhase 1
29
Roxadustat + PlaceboAstellas PharmaPhase 3
40
RoxadustatAstellas PharmaPre-clinical
26
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40